1249 completed. 1249 Phase 3, 148 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1249 | Completed 1249 |
| Phase 2 | 148 | Completed 148 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) Linaprazan glurate 50 mg Twice Daily (BID), Linaprazan Glurate 50 mg Once Daily (QD), Lansoprazole 30 mg Once Daily (QD) - GERD (Gastroesophageal Reflux Disease) | Phase 3 | Completed | Cinclus Pharma Holding AB | 523 | 2025-09-11 | 2026-10-21 |
| Alginate vs Sucralfate for GERD Symptomatic Relief Alginate, Sucralfate - GERD | Phase 2 / Phase 3 | Completed | CMH Lahore Medical College and Institute of Dentistry | 140 | 2025-04-01 | 2026-07-15 |
| Effects of Standardized Boswellia Carterii Extract on Irritable Bowel Syndrome Patients Boswellia carterii Extract, Educationntal program for IBS patie - Irritable Bowel Syndrome | Phase 2 / Phase 3 | Completed | Mansoura University | 60 | 2025-01-01 | 2026-05-08 |
| Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease Fexuprazan, Esomeprazole - Gastro Oesophageal Reflux Disease | Phase 3 | Completed | Universitas Indonesia | 145 | 2024-08-28 | 2026-08-24 |
| 7 Days vs. 14 Days of Vonoprazan-based Triple Therapy for H. Pylori Eradication Vonoprazan, Amoxicillin, Clarithromycin - Helicobacter Pylori Infection, Gastritis | Phase 3 | Completed | Alexandria University | 326 | 2024-06-30 | 2025-02-11 |
| The Effects of Bromelain Supplement in Patients With Ulcerative Colitis Bromlein, Placebo - Ulcerative Colitis, Primary Sclerosing Cholangitis | Phase 2 / Phase 3 | Completed | National Nutrition and Food Technology Institute | 52 | 2024-04-20 | 2026-10-27 |
| A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants HRV PCV-free, IPV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 400 | 2024-03-22 | 2025-10-22 |
| Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis Tradipitant - Idiopathic Gastroparesis, Diabetic Gastroparesis | Phase 3 | Completed | Vanda Pharmaceuticals | 17 | 2024-01-09 | 2026-10-19 |
| Optimizing Early Nutrition Support in Severe Stroke-2 Trophic enteral feeding combined with supplemental parenteral nutrition, Full enteral feeding - Severe Stroke, Acute Stroke | Phase 3 | Completed | Wen Jiang-3 | 546 | 2023-12-20 | 2026-06-24 |
| A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis Mirikizumab IV, Mirikizumab SC - Ulcerative Colitis | Phase 3 | Completed | Eli Lilly and Company | 63 | 2023-11-22 | 2026-06-03 |
| Gamma-irradiated Amniotic Membrane Graft in Posterior Colporrhaphy posterior colporrhaphy using gamma-irradiated amniotic membrane as a graft - Rectocele; Female, Pelvic Organ Prolapse | Phase 3 | Completed | Ain Shams Maternity Hospital | 25 | 2023-11-01 | 2025-12-02 |
| Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks GSK's liquid oral live attenuated HRV, PCV-free liquid formulation of GSK's oral live attenuated HRV - Gastroenteritis | Phase 3 | Completed | GlaxoSmithKline | 2000 | 2023-09-01 | 2025-05-09 |
| Dapagliflozin in Patients With Ulcerative Colitis Mesalamine, Dapagliflozin 10mg Tab - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 60 | 2023-08-20 | 2026-09-21 |
| Clinical Study to Evaluate the Possible Efficacy of Nifuroxazide in Patient With Ulcerative Colitis Mesalamine, Nifuroxazide - Inflammatory Bowel Diseases | Phase 2 / Phase 3 | Completed | Mostafa Bahaa | 50 | 2023-08-20 | 2026-10-13 |
| Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines HIL-214, Placebo - Gastroenteritis | Phase 2 / Phase 3 | Completed | HilleVax | 329 | 2023-06-10 | 2025-03-12 |
| Comparison of Ketorolac at Three Doses in Children With Acute Pain Ketorolac Tromethamine - Acute Pain, Abdominal Pain | Phase 3 | Completed | Hamilton Health Sciences Corporation | 171 | 2023-06-01 | 2025-07-09 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis Mirikizumab - Ulcerative Colitis, Ulcerative Colitis Chronic | Phase 3 | Completed | Eli Lilly and Company | 172 | 2023-05-17 | 2026-06-10 |
| A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection RBX2660 - Clostridium Difficile Infection Recurrence | Phase 3 | Completed | Ferring Pharmaceuticals | 41 | 2023-04-21 | 2026-04-24 |
| A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease BLI5100 - Non-erosive Reflux Disease, Erosive Esophagitis | Phase 3 | Completed | Braintree Laboratories | 400 | 2023-04-05 | 2025-09-26 |
| A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer HIP0612, HPP2202, RLD2204 - Gastric Ulcer | Phase 3 | Completed | Hanmi Pharmaceutical Company Limited | 199 | 2023-03-06 | 2025-02-19 |
Showing 20 of 1249. Sign in to see all of them.
Colorectal Neoplasms (237) · Colitis, Ulcerative (123) · Crohn Disease (122) · Stomach Neoplasms (119) · Colonic Neoplasms (107) · Rectal Neoplasms (101) · Gastroesophageal Reflux (88) · Esophageal Neoplasms (48) · Inflammatory Bowel Diseases (48) · Irritable Bowel Syndrome (39) · Stomach Ulcer (38) · Gastroenteritis (37) · Neoplasm Metastasis (35) · Diarrhea (32)
Digestive System Diseases (1234) · Intestinal Diseases (799) · Digestive System Neoplasms (518) · Neoplasms (518) · Neoplasms by Site (514) · Gastrointestinal Neoplasms (506) · Colonic Diseases (451) · Gastroenteritis (352) · Intestinal Neoplasms (320) · Rectal Diseases (312) · Pathological Conditions, Signs and Symptoms (259) · Esophageal Diseases (210) · Inflammatory Bowel Diseases (202) · Stomach Diseases (196)
Fluorouracil (136) · Leucovorin (99) · Oxaliplatin (91) · Capecitabine (70) · Cisplatin (52) · Irinotecan (52) · Bevacizumab (48) · Mesalamine (43) · Esomeprazole (42) · Adalimumab (34) · Radiotherapy (32) · Lansoprazole (28) · Cetuximab (25) · Paclitaxel (22) · Docetaxel (20)
Takeda (44) · AstraZeneca (40) · Hoffmann-La Roche (26) · Shire (25) · Merck Sharp & Dohme LLC (21) · Bausch Health Americas, Inc. (18) · Alliance for Clinical Trials in Oncology (17) · National Cancer Institute (NCI) (16) · AbbVie (14) · Abbott (14) · Chinese University of Hong Kong (14) · Pfizer (13) · Amgen (12) · Dr. Falk Pharma GmbH (12) · Sanofi (11)
United States (457) · Canada (253) · Germany (240) · France (235) · United Kingdom (196) · Italy (194) · Belgium (184) · Japan (172) · Spain (171) · South Korea (168) · Poland (167) · Australia (156) · China (142) · Netherlands (130) · Hungary (123)
PMID 29380251, PMID 36306483, PMID 19735233, PMID 31268130, PMID 32445184, PMID 33356421, PMID 21129076, PMID 30679026, PMID 31378656, PMID 37368103, PMID 20195905, PMID 20526599, PMID 21997132, PMID 26893500, PMID 29850873, PMID 30476584, PMID 31077827, PMID 31599001, PMID 32085892, PMID 32635680, PMID 32766762, PMID 32816215, PMID 32870265, PMID 32964215, PMID 33324993, PMID 33684552, PMID 34614208, PMID 35648151, PMID 35792493, PMID 36124702, PMID 36336750, PMID 36342120, PMID 36526796, PMID 36931693, PMID 37402275, PMID 37560161, PMID 38310565, PMID 38425446, PMID 40357993, PMID 23451835, PMID 24118079, PMID 25996351, PMID 26049686, PMID 26563167, PMID 27959607, PMID 28467869, PMID 29028981, PMID 29142515, PMID 29409871, PMID 29627309
2015 (21), 2016 (17), 2017 (16), 2014 (13), 2004 (10), 2008 (10), 2018 (10), 2023 (9), 2019 (8), 2009 (7), U10CA031946 (7), 2005 (5), U10CA012027 (4), U10CA021115 (4), U01CA121947 (2)